Diana Zuckerman is president of the National Center for Health Research, a nonprofit think tank based in Washington, D.C.

Diana Zuckerman
President
National Center for Health Research
From this contributor
How the new U.S. ‘Right to Try’ law could harm people with autism
People with autism already have access to experimental treatments; the new law could make that access more dangerous.

How the new U.S. ‘Right to Try’ law could harm people with autism
Why the 21st Century Cures Act could be disastrous for medicine
A new bill threatens to lower the scientific standards that have made the Food and Drug Administration's approval the gold standard worldwide.

Why the 21st Century Cures Act could be disastrous for medicine
Explore more from The Transmitter
Machine learning spots neural progenitors in adult human brains
But the finding has not settled the long-standing debate over the existence and extent of neurogenesis during adulthood, says Yale University neuroscientist Juan Arellano.

Machine learning spots neural progenitors in adult human brains
But the finding has not settled the long-standing debate over the existence and extent of neurogenesis during adulthood, says Yale University neuroscientist Juan Arellano.
Xiao-Jing Wang outlines the future of theoretical neuroscience
Wang discusses why he decided the time was right for a new theoretical neuroscience textbook and how bifurcation is a key missing concept in neuroscience explanations.
Xiao-Jing Wang outlines the future of theoretical neuroscience
Wang discusses why he decided the time was right for a new theoretical neuroscience textbook and how bifurcation is a key missing concept in neuroscience explanations.
Memory study sparks debate over statistical methods
Critics of a 2024 Nature paper suggest the authors failed to address the risk of false-positive findings. The authors argue more rigorous methods can result in missed leads.

Memory study sparks debate over statistical methods
Critics of a 2024 Nature paper suggest the authors failed to address the risk of false-positive findings. The authors argue more rigorous methods can result in missed leads.